Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026

Black Diamond Therapeutics, Inc.

Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.
Net loss for Q4 2024 was $16.0M, compared to $19.4M in Q4 2023; FY2024 net loss $69.7M vs $82.4M.
R&D expenses decreased to $12.3M in Q4 2024 from $15.3M in Q4 2023; FY2024 R&D $51.3M vs $59.4M.
Initial Phase 2 data for BDTX-1535 in newly diagnosed non-classical EGFRm NSCLC expected Q2 2025.
Cash runway expected into Q4 2026; management to seek FDA feedback on registrational path for BDTX-1535 in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.